Many Impax Laboratories, Inc.(IPXL) Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock. Impax Laboratories Inc was Initiated by Janney on Dec 28, 2016 to Neutral, Price Target of the shares are set at $15.
Company has reported several Insider transactions to the SEC, on Aug 17, 2016, Leslie Z Benet (director) sold 10,092 shares at 22.81 per share price.On Sep 14, 2015, Michael Nestor (President, Impax Pharm.) sold 5,000 shares at 43.56 per share price.On Sep 14, 2015, Mark A Schlossberg (SVP and General Counsel) sold 7,457 shares at 43.30 per share price.
Impax Laboratories Inc Last issued its quarterly earnings results on Nov 9, 2016. The company reported $0.37 EPS for the quarter, missing the analyst consensus estimate by $ -0.02. Analyst had a consensus of $0.39. The company had revenue of $227.90 million for the quarter, compared to analysts expectations of $234.68 million. The companys revenue was up 3.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.40 EPS.
Impax Laboratories, Inc. (NASDAQ:IPXL) has received a short term rating of buy from experts at Zacks with a rank of 2. The stock has been rated an average of 2.7 by 10 Brokerage Firm. 2 Wall Street Firms have rated the stock as a strong buys. 7 Brokerage Firms have advised hold. A sell rating was given by 1 analyst.
Impax Laboratories, Inc. (NASDAQ:IPXL) stock has received a short term price target of $ 18.33 from 9 Analyst. The share price can be expected to fluctuate from the mean short term target, can be seen from the standard deviation reading of $4.74. The higher estimate of target price is $30 , while the lower price target estimate is $15
Impax Laboratories, Inc. (NASDAQ:IPXL) rose 2.17% or 0.3 points on Tuesday and made its way into the gainers of the day. After trading began at $13.75 the stock was seen hitting $14.3 as a peak level and $13.75 as the lowest level. The stock ended up at $14.1. The daily volume was measured at 1,041,304 shares. The 52-week high of the share price is $37.2 and the 52-week low is $11.65. The company has a market cap of $1,042 million.
Impax Laboratories, Inc. is a technology-based, specialty pharmaceutical company engaged in the development, manufacture, and marketing of specialty prescription pharmaceutical products utilizing its own formulation expertise and drug delivery technologies. IMPAX Laboratories is focusing on two key areas, namely Generic Pharmaceutical Products and Branded Pharmaceutical Products. In the generic pharmaceuticals market, it focuses its efforts on controlled-release generic versions of selected brand-name pharmaceuticals covering a range of therapeutic areas. In the brand-name pharmaceuticals market, Impax is developing products for the treatment of central nervous system disorders. The company sells its products to large pharmaceutical wholesalers, warehousing chain drug stores, mass merchandisers, and mail-order pharmacies through strategic alliances and the companys global pharmaceuticals division.